Skip to content

Study · Randomized controlled trial · n = 64 · 2020

15 results

Liraglutide treatment in overweight and obese patients with type 1 diabetes: A 26-week randomized controlled trial; mechanisms of weight loss.

Ghanim H, Batra M, Green K, Abuaysheh S, Hejna J, Makdissi A, Borowski R, Kuhadiya ND, Chaudhuri A, Dandona P

Diabetes, obesity & metabolism8 Jul 2020Cited by 71 (Europe PMC)

PMID32424935 (opens in a new tab)DOI10.1111/dom.14090 (opens in a new tab)PepBankPUB-32424935
Publisher pagePubMedAsk about this study
Jump to 15 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study15

15 results from studies that gave the peptide. 15 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In overweight and obese adults with type 1 diabetes, the HbA1c difference between liraglutide and placebo was not significant.

    In plain wordsIn overweight adults with type 1 diabetes, the HbA1c drop with liraglutide was not clearly different from placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeHbA1c difference vs placebo
    Study

    n = 64

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg/d · 6 monthsAs given in this study (human).

    Measurements

    HbA1c difference vs placebo
    0.29%
    liraglutide

    Source sentences

    Summary
    Glycated haemoglobin fell by 0.41 ± 0.18% (4.5±1.4 mmol/mol) from baseline after liraglutide treatment (P = 0.001), and by 0.29 ± 0.19% (3.1±2.0 mmol/mol) compared to placebo (P = 0.1).
    1 context sentence
    Summary · context
    A total of 84 adult overweight and obese patients with T1DM, with no detectable C-peptide, were randomized (1:1) to either placebo or 1.8 mg/d liraglutide for 6 months.
  2. 02HumanRandomized controlled trialSafety outcome

    In overweight and obese adults with type 1 diabetes, liraglutide did not increase hypoglycaemia.

    In plain wordsIn overweight adults with type 1 diabetes, liraglutide did not increase low blood sugar.

    Peptide
    Liraglutide
    Outcome
    No significant changeHypoglycaemia
    Study

    n = 64

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    1.8 mg/d · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    There was no increase in hypoglycaemia, while the time spent in normal glycaemia increased (P = 0.015) and time spent in hyperglycaemia decreased (P = 0.019).
    1 context sentence
    Summary · context
    A total of 84 adult overweight and obese patients with T1DM, with no detectable C-peptide, were randomized (1:1) to either placebo or 1.8 mg/d liraglutide for 6 months.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In overweight and obese adults with type 1 diabetes, liraglutide increased time spent in normal glycaemia.

    In plain wordsIn overweight adults with type 1 diabetes, liraglutide increased the time spent with normal blood sugar.

    Peptide
    Liraglutide
    Outcome
    IncreaseTime spent in normal glycaemia
    Study

    n = 64

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg/d · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    There was no increase in hypoglycaemia, while the time spent in normal glycaemia increased (P = 0.015) and time spent in hyperglycaemia decreased (P = 0.019).
    1 context sentence
    Summary · context
    A total of 84 adult overweight and obese patients with T1DM, with no detectable C-peptide, were randomized (1:1) to either placebo or 1.8 mg/d liraglutide for 6 months.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In overweight and obese adults with type 1 diabetes, liraglutide decreased time spent in hyperglycaemia.

    In plain wordsIn overweight adults with type 1 diabetes, liraglutide reduced the time spent with high blood sugar.

    Peptide
    Liraglutide
    Outcome
    DecreaseTime spent in hyperglycaemia
    Study

    n = 64

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg/d · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    There was no increase in hypoglycaemia, while the time spent in normal glycaemia increased (P = 0.015) and time spent in hyperglycaemia decreased (P = 0.019).
    1 context sentence
    Summary · context
    A total of 84 adult overweight and obese patients with T1DM, with no detectable C-peptide, were randomized (1:1) to either placebo or 1.8 mg/d liraglutide for 6 months.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In overweight and obese adults with type 1 diabetes, HbA1c fell from baseline after liraglutide treatment.

    In plain wordsIn overweight adults with type 1 diabetes, HbA1c fell from baseline during liraglutide treatment.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change from baseline
    Study

    n = 37

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg/d · 6 monthsAs given in this study (human).

    Measurements

    HbA1c change from baseline
    0.41%
    liraglutide, fall

    Source sentences

    Summary
    Glycated haemoglobin fell by 0.41 ± 0.18% (4.5±1.4 mmol/mol) from baseline after liraglutide treatment (P = 0.001)
    2 context sentences
    Summary · context
    In all, 37 and 27 patients who received liraglutide and placebo, respectively, completed the study.
    Summary · context
    A total of 84 adult overweight and obese patients with T1DM, with no detectable C-peptide, were randomized (1:1) to either placebo or 1.8 mg/d liraglutide for 6 months.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In overweight and obese adults with type 1 diabetes, body weight fell significantly in the liraglutide group.

    In plain wordsIn overweight adults with type 1 diabetes, body weight fell in the liraglutide group.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight
    Study

    n = 37

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.8 mg/d · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Body weight fell significantly in the liraglutide group, mostly in the form of fat mass loss (including visceral fat), with no change in lean mass.
    1 context sentence
    Summary · context
    A total of 84 adult overweight and obese patients with T1DM, with no detectable C-peptide, were randomized (1:1) to either placebo or 1.8 mg/d liraglutide for 6 months.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In overweight and obese adults with type 1 diabetes, weight loss with liraglutide was mostly fat mass loss, including visceral fat.

    In plain wordsIn overweight adults with type 1 diabetes, weight lost on liraglutide was mostly fat, including belly fat.

    Peptide
    Liraglutide
    Outcome
    DecreaseFat mass including visceral fat
    Study

    n = 37

    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    1.8 mg/d · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Body weight fell significantly in the liraglutide group, mostly in the form of fat mass loss (including visceral fat), with no change in lean mass.
    1 context sentence
    Summary · context
    A total of 84 adult overweight and obese patients with T1DM, with no detectable C-peptide, were randomized (1:1) to either placebo or 1.8 mg/d liraglutide for 6 months.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In overweight and obese adults with type 1 diabetes, lean mass did not change with liraglutide.

    In plain wordsIn overweight adults with type 1 diabetes, lean body mass did not change with liraglutide.

    Peptide
    Liraglutide
    Outcome
    No significant changeLean mass
    Study

    n = 37

    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    1.8 mg/d · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Body weight fell significantly in the liraglutide group, mostly in the form of fat mass loss (including visceral fat), with no change in lean mass.
    1 context sentence
    Summary · context
    A total of 84 adult overweight and obese patients with T1DM, with no detectable C-peptide, were randomized (1:1) to either placebo or 1.8 mg/d liraglutide for 6 months.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In overweight and obese adults with type 1 diabetes, systolic blood pressure fell after liraglutide treatment.

    In plain wordsIn overweight adults with type 1 diabetes, systolic blood pressure fell after liraglutide treatment.

    Peptide
    Liraglutide
    Outcome
    DecreaseSystolic blood pressure
    Study

    n = 37

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    1.8 mg/d · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Systolic blood pressure (SBP) also fell after liraglutide treatment.
    1 context sentence
    Summary · context
    A total of 84 adult overweight and obese patients with T1DM, with no detectable C-peptide, were randomized (1:1) to either placebo or 1.8 mg/d liraglutide for 6 months.
  10. 10HumanRandomized controlled trialMechanism

    In overweight and obese adults with type 1 diabetes, liraglutide increased adipose tissue expression of triglyceride lipase.

    In plain wordsIn overweight adults with type 1 diabetes, liraglutide increased fat tissue activity of a gene for fat breakdown.

    Peptide
    Liraglutide
    Outcome
    IncreaseAdipose tissue triglyceride lipase expression
    Study

    n: not reported in source

    Outcome group
    Fat metabolism and adipogenesis · Metabolic and weight
    Studied dose
    1.8 mg/d · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Liraglutide also caused a significant increase in the expression of adipose tissue triglyceride lipase, carnitine palmitoyl transferase-1, peroxisome proliferator-activated receptor (PPAR)α, PPARδ, uncoupling protein-2 and type 2 iodothyronine deiodinase in the adipose tissue.
    1 context sentence
    Summary · context
    A total of 84 adult overweight and obese patients with T1DM, with no detectable C-peptide, were randomized (1:1) to either placebo or 1.8 mg/d liraglutide for 6 months.
  11. 11HumanRandomized controlled trialMechanism

    In overweight and obese adults with type 1 diabetes, liraglutide increased adipose tissue expression of carnitine palmitoyl transferase-1.

    In plain wordsIn overweight adults with type 1 diabetes, liraglutide increased fat tissue activity of a gene for fat burning.

    Peptide
    Liraglutide
    Outcome
    IncreaseAdipose carnitine palmitoyl transferase-1 expression
    Study

    n: not reported in source

    Outcome group
    Fat metabolism and adipogenesis · Metabolic and weight
    Studied dose
    1.8 mg/d · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Liraglutide also caused a significant increase in the expression of adipose tissue triglyceride lipase, carnitine palmitoyl transferase-1, peroxisome proliferator-activated receptor (PPAR)α, PPARδ, uncoupling protein-2 and type 2 iodothyronine deiodinase in the adipose tissue.
    1 context sentence
    Summary · context
    A total of 84 adult overweight and obese patients with T1DM, with no detectable C-peptide, were randomized (1:1) to either placebo or 1.8 mg/d liraglutide for 6 months.
  12. 12HumanRandomized controlled trialMechanism

    In overweight and obese adults with type 1 diabetes, liraglutide increased adipose tissue expression of PPARα.

    In plain wordsIn overweight adults with type 1 diabetes, liraglutide increased fat tissue activity of the PPARα gene.

    Peptide
    Liraglutide
    Outcome
    IncreaseAdipose PPARα expression
    Study

    n: not reported in source

    Outcome group
    Fat metabolism and adipogenesis · Metabolic and weight
    Studied dose
    1.8 mg/d · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Liraglutide also caused a significant increase in the expression of adipose tissue triglyceride lipase, carnitine palmitoyl transferase-1, peroxisome proliferator-activated receptor (PPAR)α, PPARδ, uncoupling protein-2 and type 2 iodothyronine deiodinase in the adipose tissue.
    1 context sentence
    Summary · context
    A total of 84 adult overweight and obese patients with T1DM, with no detectable C-peptide, were randomized (1:1) to either placebo or 1.8 mg/d liraglutide for 6 months.
  13. 13HumanRandomized controlled trialMechanism

    In overweight and obese adults with type 1 diabetes, liraglutide increased adipose tissue expression of PPARδ.

    In plain wordsIn overweight adults with type 1 diabetes, liraglutide increased fat tissue activity of the PPARδ gene.

    Peptide
    Liraglutide
    Outcome
    IncreaseAdipose PPARδ expression
    Study

    n: not reported in source

    Outcome group
    Fat metabolism and adipogenesis · Metabolic and weight
    Studied dose
    1.8 mg/d · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Liraglutide also caused a significant increase in the expression of adipose tissue triglyceride lipase, carnitine palmitoyl transferase-1, peroxisome proliferator-activated receptor (PPAR)α, PPARδ, uncoupling protein-2 and type 2 iodothyronine deiodinase in the adipose tissue.
    1 context sentence
    Summary · context
    A total of 84 adult overweight and obese patients with T1DM, with no detectable C-peptide, were randomized (1:1) to either placebo or 1.8 mg/d liraglutide for 6 months.
  14. 14HumanRandomized controlled trialMechanism

    In overweight and obese adults with type 1 diabetes, liraglutide increased adipose tissue expression of uncoupling protein-2.

    In plain wordsIn overweight adults with type 1 diabetes, liraglutide increased fat tissue activity of the uncoupling protein-2 gene.

    Peptide
    Liraglutide
    Outcome
    IncreaseAdipose uncoupling protein-2 expression
    Study

    n: not reported in source

    Outcome group
    Fat metabolism and adipogenesis · Metabolic and weight
    Studied dose
    1.8 mg/d · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Liraglutide also caused a significant increase in the expression of adipose tissue triglyceride lipase, carnitine palmitoyl transferase-1, peroxisome proliferator-activated receptor (PPAR)α, PPARδ, uncoupling protein-2 and type 2 iodothyronine deiodinase in the adipose tissue.
    1 context sentence
    Summary · context
    A total of 84 adult overweight and obese patients with T1DM, with no detectable C-peptide, were randomized (1:1) to either placebo or 1.8 mg/d liraglutide for 6 months.
  15. 15HumanRandomized controlled trialMechanism

    In overweight and obese adults with type 1 diabetes, liraglutide increased adipose tissue expression of type 2 iodothyronine deiodinase.

    In plain wordsIn overweight adults with type 1 diabetes, liraglutide increased fat tissue activity of the type 2 iodothyronine deiodinase gene.

    Peptide
    Liraglutide
    Outcome
    IncreaseAdipose type 2 iodothyronine deiodinase expression
    Study

    n: not reported in source

    Outcome group
    Fat metabolism and adipogenesis · Metabolic and weight
    Studied dose
    1.8 mg/d · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Liraglutide also caused a significant increase in the expression of adipose tissue triglyceride lipase, carnitine palmitoyl transferase-1, peroxisome proliferator-activated receptor (PPAR)α, PPARδ, uncoupling protein-2 and type 2 iodothyronine deiodinase in the adipose tissue.
    1 context sentence
    Summary · context
    A total of 84 adult overweight and obese patients with T1DM, with no detectable C-peptide, were randomized (1:1) to either placebo or 1.8 mg/d liraglutide for 6 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.